Media headlines about SAGE Therapeutics (NASDAQ:SAGE) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. SAGE Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.493848963895 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research firms have recently commented on SAGE. BidaskClub raised SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 3rd. JPMorgan Chase reissued a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, January 10th. Cowen reissued a “buy” rating and set a $202.00 target price on shares of SAGE Therapeutics in a research note on Tuesday, March 20th. Morgan Stanley assumed coverage on SAGE Therapeutics in a research note on Monday, February 26th. They set an “overweight” rating and a $225.00 target price on the stock. Finally, SunTrust Banks lifted their target price on SAGE Therapeutics to $203.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $185.20.
SAGE traded up $1.30 on Friday, hitting $170.58. 391,438 shares of the company’s stock traded hands, compared to its average volume of 496,856. The company has a market capitalization of $7,749.29, a PE ratio of -24.06 and a beta of 3.03. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97.
SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.23. During the same period in the prior year, the company posted ($1.50) earnings per share. equities research analysts predict that SAGE Therapeutics will post -8.34 EPS for the current year.
In other SAGE Therapeutics news, Director Steven M. Paul sold 58,139 shares of SAGE Therapeutics stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $172.00, for a total value of $9,999,908.00. Following the sale, the director now owns 632,712 shares of the company’s stock, valued at approximately $108,826,464. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 6.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/16/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-sage-therapeutics-sage-share-price.html.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.